Budhram, Adrian
Britton, Jeffrey W. http://orcid.org/0000-0002-0147-8159
Liebo, Greta B.
Dubey, Divyanshu
Zekeridou, Anastasia
Flanagan, Eoin P.
McKeon, Andrew
Pittock, Sean J.
Braksick, Sherri A.
Zalewski, Nicholas L.
Article History
Received: 10 April 2020
Revised: 14 June 2020
Accepted: 17 June 2020
First Online: 24 June 2020
Compliance with ethical standards
:
: Dr. Adrian Budhram has no disclosures to report. Dr. Jeff Britton is a consultant for UCB pharmaceuticals, investigational drug discussion, Rozanolixizumab; a co-investigator, unpaid, for GW Pharma in a double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experience inadequately-controlled seizures; a co-investigator, unpaid, for Grifols Pharmaceuticals in a Randomized Double-Blind Placebo Controlled Study of IVIG in Patients with Voltage-Gated Potassium Channel Complex Antibody Associated Autoimmune Epilepsy. Dr. Greta Liebo has no disclosures to report. Dr. Divyanshu Dubey has a patent pending for Kelch-like protein 11 as a marker of neurological autoimmunity and has received research support from Grifols, Translational Research Innovation and Test Development Office and, Center for Clinical and Translational Science. Dr. Dubey has consulted for UCB and Astellas. All compensation for consulting activities is paid directly to Mayo Clinic. Dr. Anastasia Zekeridou has a patent pending on PDE10A-IgG as a biomarker of neurological autoimmunity. Dr. Eoin Flanagan is a site principal investigator in a randomized placebo-controlled clinical trial of Inebilizumab (A CD19 inhibitor) in neuromyelitis optica spectrum disorders funded by MedImmune/Viela Bio. He receives no personal compensation and just receives reimbursement for the research activities related to the trial. Dr. Andrew McKeon reports grants from Alexion, grants from Grifols, grants from Euroimmun, outside the submitted work; in addition, Dr. McKeon has a patent Septin-5-IgG pending, a patent PDE10A-IgG pending, a patent MAP1B-IgG pending, and a patent GFAP-IgG pending. Dr. Sean Pittock reports grants, personal fees and non-financial support from Alexion Pharmaceuticals, Inc.; grants from Grifols, Autoimmune Encephalitis Alliance; grants, personal fees, non-financial support and other from MedImmune, Inc.; Dr. Pittock has a patent # 9,891,219 (Application#12-573942) “Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive”. Dr Pittock also has patents pending for the following IgGs as biomarkers of autoimmune neurological disorders (septin-5, Kelch-like protein 11, GFAP, PDE10A and MAP1B). Dr. Sherri Braksick has no disclosures to report. Dr. Nicholas Zalewski has no disclosures to report.
: The Mayo Clinic Institutional Review Board (IRB) approved the study (IRB number 08‐006647).
: As patients were identified retrospectively informed consent was not specifically obtained for this submission, but the patients did agree to use of their medical records for research purposes and no patient-identifying images have been included.
: The authors consent to the publication of this manuscript. The manuscript and figures have not been published or copyrighted elsewhere.